Spots Global Cancer Trial Database for recurrent malignant solid neoplasm

Every month we try and update this database with for recurrent malignant solid neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	NCT00939770	Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur...	Crizotinib Laboratory Biom... Pharmacological... Questionnaire A...	1 Year - 21 Years	Children's Oncology Group
Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer	NCT05058339	Advanced Malign... COVID-19 Infect... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Hemat... Recurrent Malig...	Survey Administ...	18 Years -	M.D. Anderson Cancer Center
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	NCT02867592	Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor	Cabozantinib Cabozantinib S-... Pharmacological...	2 Years - 30 Years	National Cancer Institute (NCI)
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02975882	Childhood Solid... Recurrent Malig... Recurrent Prima... Refractory Mali... Refractory Prim...	Irinotecan Hydr... Laboratory Biom... Pharmacological... Sirolimus Album... Temozolomide	12 Months - 21 Years	Children's Oncology Group
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors	NCT04840589	Metastatic Mali... Recurrent Malig... Recurrent Plati... Refractory Ovar...	BET Bromodomain... Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Positron Emissi... X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors	NCT06320405	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Axatilimab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Paclitaxel Positron Emissi... Retifanlimab	18 Years -	OHSU Knight Cancer Institute
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors	NCT04840589	Metastatic Mali... Recurrent Malig... Recurrent Plati... Refractory Ovar...	BET Bromodomain... Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Positron Emissi... X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	NCT03220035	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor	Laboratory Biom... Vemurafenib	12 Months - 21 Years	National Cancer Institute (NCI)
Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis	NCT05059678	Metastatic Mali... Recurrent Malig...	Best Practice Educational Int... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02780804	Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu...	Entinostat Laboratory Biom... Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03698994	Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor	Pharmacokinetic... Ulixertinib	12 Months - 21 Years	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	NCT01709435	Recurrent Malig... Recurrent Melan... Recurrent Prima... Recurrent Thyro... Refractory Mali... Refractory Prim... Thyroid Gland M...	Cabozantinib S-... Laboratory Biom... Pharmacological...	2 Years - 18 Years	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	NCT04119024	Metastatic Mali... Metastatic Mela... Pathologic Stag... Pathologic Stag... Recurrent Malig... Refractory Mali... Uveal Melanoma Acral Melanoma Neuroendocrine ... Paraganglioma Pheochromocytom... Adrenocortical ... Pancreatic Neur... Thyroid Cancer Breast Cancer Lung Adenocarci... Head and Neck S...	Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Pho... Fludeoxyglucose... IL13Ralpha2-spe... Magnetic Resona... Positron Emissi...	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer	NCT03927885	Advanced Malign... Metastatic Mali... Recurrent Malig...	Placebo Adminis... Quality-of-Life... Questionnaire A... Waiting List	18 Years -	M.D. Anderson Cancer Center
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)	NCT06126276	Malignant Femal... Malignant Solid... Recurrent Malig... Recurrent Malig...	Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Neratinib Malea... Palbociclib	18 Years -	National Cancer Institute (NCI)
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites	NCT04267575	Recurrent Malig... Stage IV Breast... Stage IV Prosta... Stage IV Pancre... Stage IV Non-sm... Stage IV Ovaria... Stage IV Fallop... Stage IV Colon ... Stage IV Colore... Stage IV Liver ... Stage IV Renal ... Stage IV Rectal... Stage IV Lung C... Stage IV Small ... Stage IV Gastri... Stage IV Bladde...	Canady Helios C...	18 Years -	Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors	NCT03320330	Recurrent Malig... Recurrent Osteo... Refractory Mali... Refractory Oste...	Laboratory Biom... Pepinemab Pharmacological...	12 Months - 30 Years	Children's Oncology Group
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	NCT00939770	Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur...	Crizotinib Laboratory Biom... Pharmacological... Questionnaire A...	1 Year - 21 Years	Children's Oncology Group
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus	NCT01822522	Advanced Malign... HIV Infection Metastatic Mali... Recurrent Malig... Unresectable So...	Cabozantinib S-... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer	NCT02451553	Advanced Malign... Bile Duct Carci... Recurrent Malig... Recurrent Pancr... Stage III Pancr... Stage IVA Pancr... Stage IVB Pancr...	Afatinib Dimale... Capecitabine Laboratory Biom...	19 Years -	University of Washington
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment	NCT05455606	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Best Practice Chart Abstracti... Educational Int... Genomic Profile Interview Questionnaire A... Tumor Board Rev...	18 Years -	SWOG Cancer Research Network
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	NCT03428802	BRCA1 Gene Muta... BRCA2 Gene Muta... Locally Advance... Metastatic Mali... POLD1 Gene Muta... POLE Gene Mutat... Recurrent Malig... Recurrent Ovari... Stage III Breas... Stage III Ovari... Stage IIIA Brea... Stage IIIA Ovar... Stage IIIB Brea... Stage IIIB Ovar... Stage IIIC Brea... Stage IIIC Ovar... Stage IV Breast... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari...	Laboratory Biom... Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial	NCT04693468	Advanced Malign... Metastatic Mali... Recurrent Malig...	Axitinib Crizotinib Palbociclib Ise... Talazoparib Tos...	18 Years -	M.D. Anderson Cancer Center
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	NCT05010096	Locally Advance... Metastatic Mali... Metastatic Mali... Recurrent Malig...	Copanlisib Elimusertib	18 Years -	M.D. Anderson Cancer Center
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations	NCT03212274	Advanced Malign... Glioblastoma Recurrent Chola... Recurrent Gliom... Recurrent Malig... WHO Grade 2 Gli... WHO Grade 3 Gli...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib	18 Years -	National Cancer Institute (NCI)
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	NCT03213678	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Malignant Gliom... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor	Biospecimen Col... Computed Tomogr... FDG-Positron Em... Magnetic Resona... Samotolisib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites	NCT04267575	Recurrent Malig... Stage IV Breast... Stage IV Prosta... Stage IV Pancre... Stage IV Non-sm... Stage IV Ovaria... Stage IV Fallop... Stage IV Colon ... Stage IV Colore... Stage IV Liver ... Stage IV Renal ... Stage IV Rectal... Stage IV Lung C... Stage IV Small ... Stage IV Gastri... Stage IV Bladde...	Canady Helios C...	18 Years -	Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04320888	Hematopoietic a... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Lymph... Recurrent Malig... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent WHO G... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Lymp... Refractory Mali... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory WHO ... Wilms Tumor	Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Selpercatinib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	NCT05010096	Locally Advance... Metastatic Mali... Metastatic Mali... Recurrent Malig...	Copanlisib Elimusertib	18 Years -	M.D. Anderson Cancer Center
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	NCT03220035	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor	Laboratory Biom... Vemurafenib	12 Months - 21 Years	National Cancer Institute (NCI)
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors	NCT03035409	Advanced Malign... C-Reactive Prot... Cancer Fatigue Metastatic Mali... Recurrent Malig... Weight Loss	Anamorelin Hydr... Exercise Interv... Laboratory Biom... Nutritional Ass... Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03698994	Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor	Pharmacokinetic... Ulixertinib	12 Months - 21 Years	National Cancer Institute (NCI)
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma	NCT05101356	Advanced Adenoc... Advanced Malign... Metastatic Aden... Metastatic Mali... Recurrent Adeno... Recurrent Malig...	Antineoplastic ... Sargramostim Pembrolizumab	18 Years -	University of California, Davis
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study	NCT04500548	Constitutional ... Hematopoietic a... Lynch Syndrome Recurrent Lymph... Recurrent Malig... Recurrent Neuro... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Neur... Refractory Prim... Xeroderma Pigme...	Biospecimen Col... Ipilimumab Nivolumab	12 Months - 25 Years	National Cancer Institute (NCI)
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02780804	Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu...	Entinostat Laboratory Biom... Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer	NCT05058339	Advanced Malign... COVID-19 Infect... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Hemat... Recurrent Malig...	Survey Administ...	18 Years -	M.D. Anderson Cancer Center
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03213691	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim...	Laboratory Biom... Selumetinib Selumetinib Sul...	12 Months - 21 Years	National Cancer Institute (NCI)
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma	NCT03323034	Recurrent Lymph... Recurrent Malig... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Prim...	Irinotecan Pevonedistat Temozolomide	6 Months - 21 Years	Children's Oncology Group
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	NCT05071209	Recurrent Alveo... Recurrent Ewing... Recurrent Lymph... Recurrent Malig... Refractory Alve... Refractory Ewin... Refractory Lymp... Refractory Mali...	Elimusertib	12 Months - 30 Years	National Cancer Institute (NCI)
Adoption of Audio Recording in the Outpatient Supportive Care Center	NCT04871477	Advanced Malign... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Malig...	Communication I... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	NCT02095132	Central Nervous... Central Nervous... Central Nervous... Embryonal Tumor... Pineoblastoma Primary Central... Recurrent Child... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Rhabd... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Rhab...	Adavosertib Irinotecan Hydr...	1 Year - 21 Years	National Cancer Institute (NCI)
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors	NCT03366103	Metastatic Mali... Recurrent Lung ... Recurrent Malig... Refractory Mali... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung S... Unresectable So...	Navitoclax Vistusertib	18 Years -	National Cancer Institute (NCI)
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	NCT03229278	Lymphoma Metastatic Mali... Metastatic Mela... Metastatic Rena... Recurrent Bladd... Recurrent Class... Recurrent Head ... Recurrent Lymph... Recurrent Malig... Recurrent Renal... Stage III Bladd... Stage III Lymph... Stage III Non-S... Stage III Renal... Stage III Skin ... Stage IIIA Non-... Stage IIIA Skin... Stage IIIB Non-... Stage IIIB Skin... Stage IIIC Skin... Stage IV Bladde... Stage IV Lympho... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Bladd... Stage IVB Bladd... Unresectable He... Unresectable So...	Enzyme Inhibito... Laboratory Biom... Nivolumab Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	NCT01709435	Recurrent Malig... Recurrent Melan... Recurrent Prima... Recurrent Thyro... Refractory Mali... Refractory Prim... Thyroid Gland M...	Cabozantinib S-... Laboratory Biom... Pharmacological...	2 Years - 18 Years	National Cancer Institute (NCI)
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors	NCT03366103	Metastatic Mali... Recurrent Lung ... Recurrent Malig... Refractory Mali... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung S... Unresectable So...	Navitoclax Vistusertib	18 Years -	National Cancer Institute (NCI)
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	NCT04851119	Colorectal Carc... Endometrial Car... Melanoma Neuroblastoma Ovarian Carcino... Pancreatic Duct... Recurrent Desmo... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Malig... Recurrent Non-H... Recurrent Osteo... Refractory Desm... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Non-... Refractory Oste... Solid Pseudopap... Wilms Tumor	Biospecimen Col... Dual X-ray Abso... Tegavivint X-Ray Imaging	12 Months - 30 Years	Children's Oncology Group
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors	NCT02389309	Advanced Malign... Recurrent Brain... Recurrent Malig... Refractory Brai...	Cyclophosphamid... Dasatinib Laboratory Biom... Temsirolimus	12 Months - 20 Years	M.D. Anderson Cancer Center
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	NCT04870944	Diffuse Midline... Metastatic Mali... Recurrent Diffu... Recurrent Lymph... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Oste... Refractory Prim...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... FACT Complex-ta...	12 Months - 30 Years	Children's Oncology Group
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus	NCT01822522	Advanced Malign... HIV Infection Metastatic Mali... Recurrent Malig... Unresectable So...	Cabozantinib S-... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment	NCT05455606	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Best Practice Chart Abstracti... Educational Int... Genomic Profile Interview Questionnaire A... Tumor Board Rev...	18 Years -	SWOG Cancer Research Network
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors	NCT03430882	Recurrent Malig... Refractory Mali...	Carboplatin Paclitaxel Sapanisertib	18 Years -	M.D. Anderson Cancer Center
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers	NCT03017833	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Neop...	Laboratory Biom... Metformin Pharmacological... Sapanisertib	18 Years -	M.D. Anderson Cancer Center
Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit	NCT05091632	Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Malig...	Electroencephal... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02780804	Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu...	Entinostat Laboratory Biom... Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	NCT03155620	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Histiocytic Sar... Juvenile Xantho... Langerhans Cell... Malignant Gliom... Recurrent Child... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Ensartinib Erdafitinib Laboratory Biom... Larotrectinib S... Magnetic Resona... Mutation Carrie... Olaparib Palbociclib Pharmacological... Positron Emissi... Radionuclide Im... Samotolisib Selpercatinib Selumetinib Sul... Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	NCT04870944	Diffuse Midline... Metastatic Mali... Recurrent Diffu... Recurrent Lymph... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Oste... Refractory Prim...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... FACT Complex-ta...	12 Months - 30 Years	Children's Oncology Group
Collection and Storage of Tissue and Blood Samples From Patients With Cancer	NCT02474160	Hematopoietic a... Malignant Solid... Metastatic Mali... Recurrent Malig...	Cytology Specim...	18 Years -	National Cancer Institute (NCI)
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma	NCT04901702	Recurrent Solid... Recurrent Ewing... Recurrent Hepat... Recurrent Malig... Recurrent Malig... Recurrent Neuro... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Wilms... Refractory Ewin... Refractory Hepa... Refractory Mali... Refractory Mali... Refractory Neur... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Soft...	Onivyde Talazoparib Temozolomide	12 Months - 30 Years	St. Jude Children's Research Hospital
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers	NCT03017833	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Neop...	Laboratory Biom... Metformin Pharmacological... Sapanisertib	18 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: